
ACKNOWLEDGMENTS

We are deeply indebted to a distinguished group of advisors for helping us in the design and conduct of this study. They include Arnold L. Potosky, Richard Kaplan, Mary McCabe, and Joseph Lipscomb at the National Cancer Institute; Jane Weeks at the Dana-Farber Cancer Institute; Robert A. Figlin at the University of California, Los Angeles; and Joel Cohen at the Agency for Healthcare Research and Quality. This study also could not be conducted without the support of many people in the research community. These include Martin Brown, Susan Hubbard, Michael Montello, and Jeanette Sian at the National Cancer Institute; Judith Wagner at the Congressional Budget Office; John Crowley, Dana Sparks, and Jeanne-Marie Smith at the Southwestern Oncology Group; Sonja Hamilton at the North Central Cancer Treatment Group; Tom Malone and Rick Magnan at the Eastern Cooperative Oncology Group; Michael Maloney at the Cancer and Leukemia Group B; and Walter Cronin at the National Surgical Adjuvant Breast and Bowel Project; Nancee Relles and Eunice Little of University of California, Los Angeles; and Samuel Bozzette, Ronald Fricker, Kathryn Davis, and Deborah Rivera at RAND.